{"transactions":[{"id":749461,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2026-06-04T22:30:14.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":35000,"derivative":{"exercise_price":8.77,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257902","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257902/ownership.xml","form_type":"4"}},{"id":801630,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:39:50.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":106875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"RSUs do not expire; they either vest or are canceled prior to the RSU vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":106875},"source":{"system":"sec-edgar","filing":"0001734755-26-000005","document":"form4-04232026_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000005/form4-04232026_080446.xml","form_type":"4"}},{"id":801629,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:39:50.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":226000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest as to 25% of the total award on August 15, 2026, and 1/12th of the remaining RSUs vest in quarterly installments thereafter on November 15, February 15, May 15 and August 15, subject to the Reporting Person's provision of service to the Issuer on each RSU vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"RSUs do not expire; they either vest or are canceled prior to the RSU vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":226000},"source":{"system":"sec-edgar","filing":"0001734755-26-000005","document":"form4-04232026_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000005/form4-04232026_080446.xml","form_type":"4"}},{"id":801628,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:39:50.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":171000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.16,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":171000},"source":{"system":"sec-edgar","filing":"0001734755-26-000005","document":"form4-04232026_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000005/form4-04232026_080446.xml","form_type":"4"}},{"id":801627,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:39:50.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":346000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 1/4th of the total grant on June 16, 2026, and 1/48th of the total grant will vest on each monthly anniversary thereafter, subject to the Reporting Person's provision of service to the Issuer on each option vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.64,"expiration_date":"2035-06-15","underlying":"Common Stock","underlying_shares":346000},"source":{"system":"sec-edgar","filing":"0001734755-26-000005","document":"form4-04232026_080446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000005/form4-04232026_080446.xml","form_type":"4"}},{"id":801626,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Common Stock","published_at":"2026-04-23T20:39:50.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4397,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001734755-26-000005","document":"form4-04232026_080446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000005/form4-04232026_080446.xml","form_type":"4"}},{"id":895648,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:13:17.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":7125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":106875,"derivative":{"underlying":"Common Stock","underlying_shares":7125},"source":{"system":"sec-edgar","filing":"0001734755-26-000004","document":"form4-02182026_100214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000004/form4-02182026_100214.xml","form_type":"4"}},{"id":895647,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Common Stock","published_at":"2026-02-18T22:13:17.000Z","date":"2026-02-17","kind":"sale","planned":false,"acquired":false,"shares":2728,"price":11.6009,"value":31647.2552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.195 to $11.8508, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":4397,"source":{"system":"sec-edgar","filing":"0001734755-26-000004","document":"form4-02182026_100214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000004/form4-02182026_100214.xml","form_type":"4"}},{"id":895646,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Common Stock","published_at":"2026-02-18T22:13:17.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":7125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":7125,"source":{"system":"sec-edgar","filing":"0001734755-26-000004","document":"form4-02182026_100214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000004/form4-02182026_100214.xml","form_type":"4"}},{"id":926739,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Restricted Stock Units","published_at":"2026-01-30T22:18:48.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":114000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":114000,"derivative":{"underlying":"Common Stock","underlying_shares":114000},"source":{"system":"sec-edgar","filing":"0001734755-26-000002","document":"form4-01302026_100145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000002/form4-01302026_100145.xml","form_type":"4"}},{"id":926738,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-01-30T22:18:48.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":171000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":171000,"derivative":{"exercise_price":11.16,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":171000},"source":{"system":"sec-edgar","filing":"0001734755-26-000002","document":"form4-01302026_100145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000173475526000002/form4-01302026_100145.xml","form_type":"4"}},{"id":1105890,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-06-18T23:42:38.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":226000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 25% of the total award on August 15, 2026, and 1/12th of the remaining RSUs vest in quarterly installments thereafter on November 15, February 15, May 15 and August 15, subject to the Reporting Person's provision of service to the Issuer on each RSU vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the RSU vesting date.."}],"balance_after":226000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":226000},"source":{"system":"sec-edgar","filing":"0001415889-25-017742","document":"form4-06182025_110634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000141588925017742/form4-06182025_110634.xml","form_type":"4"}},{"id":1105889,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research and Dev."}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-06-18T23:42:38.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":346000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4th of the total grant on June 16, 2026, and 1/48th of the total grant will vest on each monthly anniversary thereafter, subject to the Reporting Person's provision of service to the Issuer on each option vesting date."}],"balance_after":346000,"derivative":{"exercise_price":6.64,"expiration_date":"2035-06-15","underlying":"Common Stock","underlying_shares":346000},"source":{"system":"sec-edgar","filing":"0001415889-25-017742","document":"form4-06182025_110634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734755/000141588925017742/form4-06182025_110634.xml","form_type":"4"}},{"id":1119468,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-06-06T20:05:15.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":28500,"derivative":{"exercise_price":6.57,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0000950170-25-083037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025083037/ownership.xml","form_type":"4"}},{"id":1404990,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-09-17T20:10:02.000Z","date":"2024-09-13","kind":"grant","planned":false,"acquired":true,"shares":17333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":17333,"derivative":{"exercise_price":20.88,"expiration_date":"2034-09-12","underlying":"Common Stock","underlying_shares":17333},"source":{"system":"sec-edgar","filing":"0000950170-24-107272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024107272/ownership.xml","form_type":"4"}},{"id":1404989,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-09-17T20:10:02.000Z","date":"2024-09-13","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in three equal annual installments commencing on the one year anniversary of the date of grant."}],"balance_after":52000,"derivative":{"exercise_price":20.88,"expiration_date":"2034-09-12","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0000950170-24-107272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024107272/ownership.xml","form_type":"4"}},{"id":1650372,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D & MEDICAL AFFAIRS"}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:35:42.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50515,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50515},"source":{"system":"sec-edgar","filing":"0001104659-24-014692","document":"tm245865-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014692/tm245865-1_4seq1.xml","form_type":"4"}},{"id":1650371,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D & MEDICAL AFFAIRS"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:35:42.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":960000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.16,"expiration_date":"2032-12-29","underlying":"Common Stock","underlying_shares":960000},"source":{"system":"sec-edgar","filing":"0001104659-24-014692","document":"tm245865-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014692/tm245865-1_4seq1.xml","form_type":"4"}},{"id":1650370,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D & MEDICAL AFFAIRS"}}],"security":"Common Stock","published_at":"2024-02-12T16:35:42.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1327,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-014692","document":"tm245865-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014692/tm245865-1_4seq1.xml","form_type":"4"}},{"id":1659955,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D & MEDICAL AFFAIRS"}}],"security":"Restricted Stock Unit","published_at":"2024-02-05T21:29:25.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":50515,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."}],"balance_after":50515,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50515},"source":{"system":"sec-edgar","filing":"0001415889-24-002764","document":"form4-02062024_020213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002764/form4-02062024_020213.xml","form_type":"4"}},{"id":1694995,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D & MEDICAL AFFAIRS"}}],"security":"Common Stock","published_at":"2024-01-03T17:48:37.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":1327,"price":16.01,"value":21245.27,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2023 through December 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 3, 2023."}],"balance_after":1327,"source":{"system":"sec-edgar","filing":"0001415889-24-000380","document":"form4-01032024_100131.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924000380/form4-01032024_100131.xml","form_type":"4"}},{"id":2073607,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D & MEDICAL AFFAIRS"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-03T17:17:11.000Z","date":"2022-12-29","kind":"grant","acquired":true,"shares":960000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":960000,"derivative":{"exercise_price":5.16,"expiration_date":"2032-12-29","underlying":"Common Stock","underlying_shares":960000},"source":{"system":"sec-edgar","filing":"0001415889-23-000099","document":"form4-01032023_100157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923000099/form4-01032023_100157.xml","form_type":"4"}},{"id":2181768,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-17T12:19:02.000Z","date":"2022-08-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable over three years, with 33% of this option vesting on August 15, 2023, and the remainder vesting in 24 equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":1.77,"expiration_date":"2032-08-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-22-028910","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924322028910/doc4.xml","form_type":"4"}},{"id":3557300,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":41321,"kind":"person","name":"VASCONCELLES MICHAEL","position":1,"cik":"0001734755","reported_name":"VASCONCELLES MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-11T20:39:28.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":61900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vests on March 1, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer."}],"balance_after":61900,"derivative":{"exercise_price":4.36,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":61900},"source":{"system":"sec-edgar","filing":"0001209191-19-024375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1622229/000120919119024375/doc4.xml","form_type":"4"}}]}